#France #Cancer Research #Pierre Fabre #RedRidge Bio #Castres

Collaboration in Drug Discovery

Pierre Fabre Laboratories, a well-known name in the pharmaceutical field, has joined forces with RedRidge Bio, an innovative biotechnology company, to create an exclusive partnership aimed at drug discovery and development. Announced on March 12, 2025, this collaboration focuses on the development of biparatopic antibodies (BPAs), which target multiple biological pathways.

The two companies are collaborating under a new agreement where RedRidge will utilize its advanced capabilities in the design, screening, and characterization of BPAs. In parallel, Pierre Fabre will contribute its substantial drug development expertise to propel two co-development programs toward clinical development. This partnership aims to address pressing medical needs in precision oncology, dermatology, and rare diseases.

Key Features of the Agreement

Under the terms of the agreement, RedRidge will retain exclusive commercial rights in the United States, Canada, and Japan for the two collaborative programs, while Pierre Fabre will hold exclusive rights in the rest of the world. Furthermore, the agreement stipulates that Pierre Fabre will gain global exclusive rights for a third program after RedRidge transfers its rights during the preclinical phase.

Financial details of the collaboration remain undisclosed at this stage. However, it includes Pierre Fabre’s participation in RedRidge's Series A fundraising, which will be announced separately. Also outlined are royalties on initial sales, milestone payments, and research funding for the global program led by Pierre Fabre. Both parties will share the R&D expenses for the programs.

Dr. Alex Mayweg, Chairman of RedRidge’s Board and CEO of Versant Ventures, expressed enthusiasm for the partnership, stating, "This strategic alliance showcases RedRidge’s expert capabilities in drug discovery across various therapeutic targets. We are thrilled to collaborate with Pierre Fabre as a seasoned development partner and hope to build a long-term collaboration that leverages the strengths of both companies."

In response, Dr. Francesco Hofmann, Head of Healthcare R&D at Pierre Fabre Laboratories, conveyed the significance of this agreement, affirming their commitment to working with innovative biotech firms. He noted, "This alliance will allow us to harness RedRidge's cutting-edge expertise in developing biparatopic antibodies, enabling us to introduce high-quality clinical candidates addressing crucial therapeutic areas like oncology, dermatology, and rare diseases. This marks an important milestone in enriching our R&D portfolio."

This collaboration between Pierre Fabre Laboratories and RedRidge Bio exemplifies the ongoing efforts in the pharmaceutical sector to innovate and address complex health challenges. By aligning their strengths, both companies aim to accelerate the discovery of new therapeutic candidates that could potentially provide solutions for patients in need.

As the partnership develops, the healthcare community will keenly watch how this collaboration translates into innovative treatment options, particularly in the fields of oncology and dermatological therapies, which continue to demand novel approaches and solutions. With both companies committed to this strategic initiative, the potential for impactful advancements in health care looks promising.